The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy
- PMID: 19128203
- PMCID: PMC2878195
- DOI: 10.2174/187152708786927886
The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy
Abstract
Alcohol and drug abuse continue to be a major public health problem in the United States and other industrialized nations. Extensive preclinical research indicates the mesolimbic dopamine (DA) pathway and associated regions mediate the rewarding and reinforcing effects of drugs of abuse and natural rewards, such as food and sex. The serotonergic (5-HT) system, in concert with others neurotransmitter systems, plays a key role in modulating neuronal systems within the mesolimbic pathway. A substantial portion of this modulation is mediated by activity at the 5-HT3 receptor. The 5-HT3 receptor is unique among the 5-HT receptors in that it directly gates an ion channel inducing rapid depolarization that, in turn, causes the release of neurotransmitters and/or peptides. Preclinical findings indicate that antagonism of the 5-HT3 receptor in the ventral tegmental area, nucleus accumbens or amygdala reduces alcohol self-administration and/or alcohol-associated effects. Less is known about the effects of 5-HT3 receptor activity on the self-administration of other drugs of abuse or their associated effects. Clinical findings parallel the preclinical findings such that antagonism of the 5-HT3 receptor reduces alcohol consumption and some of its subjective effects. This review provides an overview of the structure, function, and pharmacology of 5-HT3 receptors, the role of these receptors in regulating DA neurotransmission in mesolimbic brain areas, and discusses data from animal and human studies implicating 5-HT3 receptors as targets for the development of new pharmacological agents to treat addictions.
Similar articles
-
The role of 5-HT3 receptors in drug dependence.Drug Alcohol Depend. 1995 May;38(2):155-71. doi: 10.1016/0376-8716(95)01120-n. Drug Alcohol Depend. 1995. PMID: 7671767 Review.
-
Contrasting effects of 5-HT3 receptor stimulation of the nucleus accumbens or ventral tegmentum on food intake in the rat.Behav Brain Res. 2017 Apr 14;323:15-23. doi: 10.1016/j.bbr.2017.01.031. Epub 2017 Jan 20. Behav Brain Res. 2017. PMID: 28115218 Free PMC article.
-
Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat.Br J Pharmacol. 1990 Feb;99(2):227-32. doi: 10.1111/j.1476-5381.1990.tb14685.x. Br J Pharmacol. 1990. PMID: 1691672 Free PMC article.
-
Ventral tegmental area 5-HT receptors: mesolimbic dopamine release and behavioural studies.Behav Brain Res. 1996;73(1-2):1-5. doi: 10.1016/0166-4328(96)00061-7. Behav Brain Res. 1996. PMID: 8788468 Review.
-
Possibility of 5-HT3 receptor involvement in alcohol dependence: a microdialysis study of nucleus accumbens dopamine and serotonin release in rats with chronic alcohol consumption.Alcohol Clin Exp Res. 1996 Dec;20(9 Suppl):311A-319A. Alcohol Clin Exp Res. 1996. PMID: 8986229
Cited by
-
Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.Pharmacol Biochem Behav. 2012 Nov;103(1):119-55. doi: 10.1016/j.pbb.2012.07.007. Epub 2012 Jul 25. Pharmacol Biochem Behav. 2012. PMID: 22841890 Free PMC article. Review.
-
The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes.J Pharmacol Exp Ther. 2010 May;333(2):547-54. doi: 10.1124/jpet.109.162594. Epub 2010 Feb 16. J Pharmacol Exp Ther. 2010. PMID: 20160007 Free PMC article.
-
Physiology and pathology of calcium signaling in the brain.Front Pharmacol. 2012 Apr 13;3:61. doi: 10.3389/fphar.2012.00061. eCollection 2012. Front Pharmacol. 2012. PMID: 22518105 Free PMC article.
-
Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin.J Psychopharmacol. 2024 Sep;38(9):818-826. doi: 10.1177/02698811241267836. Epub 2024 Sep 5. J Psychopharmacol. 2024. PMID: 39233601 Free PMC article. Clinical Trial.
-
Treatment of the psychostimulant-sensitized animal model of schizophrenia.CNS Neurosci Ther. 2011 Apr;17(2):133-9. doi: 10.1111/j.1755-5949.2010.00218.x. Epub 2010 Dec 16. CNS Neurosci Ther. 2011. PMID: 21159151 Free PMC article. Review.
References
-
- McBride WJ, Li TK. Crit Rev Neurobiol. 1998;12:339. - PubMed
-
- McBride WJ, Murphy JM, Ikemoto S. Behav Brain Res. 1999;101:129. - PubMed
-
- Spanagel R, Weiss F. Trends Neurosci. 1999;22:521. - PubMed
-
- Pierce RC, Kumaresan V. Neurosci Biobehav Rev. 2006;30:215. - PubMed
-
- Koob GF, Le Moal M. Science. 1997;278:52. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases